Loloi J, et al. - In this prospective cohort study run at a single institution, researchers focused on the treatment strategies as well as long-term consequences in acquired hemophilia A (AHA) patients and intended to offer further evidence for effective treatment and relapse timing. A prospective follow-up was performed among 25 patients who received the diagnosis of AHA between 2001 and 2017 at Penn State Hershey Medical Center. For immunosuppressive therapy (IST), prednisone and cyclophosphamide were administered initially in 19 patients, prednisone was used to treat four patients, and one was given prednisone and rituximab, and one was treated with prednisone and second-line rituximab. Findings revealed high effectiveness of IST with prednisone and cyclophosphamide in enabling the attainment as well as maintenance of complete remission, even for relapsed patients. Despite dual IST with prednisone and cyclophosphamide, the addition of second-line rituximab was needed to achieve complete remission in some patients, especially those with extremely high inhibitor titers. This implies that rituximab is an effective salvage therapy, including for cases with inhibitor titers at least 100–200 BU. Relapse, if occurred, was often experienced years after complete remission, suggesting that continued monitoring and vigilance are important.